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ABSTRACT  1 
Objective: Proton pump inhibitors (PPIs) is associated with worsening of gastric 2 
atrophy, particularly in H. pylori (HP)-infected subjects. We determined the 3 
association between PPIs use and gastric cancer (GC) among HP-infected subjects 4 
who had received HP therapy. 5 
Designs: This study was based on a territory-wide health database of Hong Kong. We 6 
identified adults who had received an outpatient prescription of clarithromycin-based 7 
triple therapy between year 2003 and 2012. Patients who failed this regimen, and 8 
those diagnosed to have GC within 12 months after HP therapy, or gastric ulcer after 9 
therapy were excluded. Prescriptions of PPIs or histamine-2 receptor antagonists 10 
(H2RA) started within 6 months before GC were excluded to avoid protopathic bias. 11 
We evaluated GC risk with PPIs by Cox proportional hazards model with propensity 12 
score adjustment. H2RA was used as a negative control exposure. 13 
Result: Among the 63,397 eligible subjects, 153 (0.24%) developed GC during a 14 
median follow-up of 7.6 years. PPIs use was associated with an increased GC risk 15 
(HR 2.44; 95% CI 1.42–4.20), while H2RA was not (HR 0.72; 95% CI:0.48–1.07). 16 
The risk increased with duration of PPIs use (HR 5.04 [95% CI:1.23–20.61], 6.65 17 
[95% CI:1.62–27.26] and 8.34 [95% CI:2.02–34.41] for ≥1 year, ≥ 2 years and ≥ 3 18 
 5 
years, respectively). The adjusted absolute risk difference for PPIs versus non-PPIs 1 
use was 4.29 excess GC (95%:CI 1.25 to 9.54) per 10,000 person-years.  2 
Conclusion: Long-term use of PPIs was still associated with an increased GC risk in 3 
subjects after HP eradication therapy. 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 6 
SIGNIFICANCE OF THIS STUDY 1 
What is already known on this subject? 2 
 Although Helicobacter pylori (H. pylori) eradication has been shown to reduce 3 
the risk of gastric cancer development, a considerable proportion of these 4 
individuals continues to progress to gastric cancer even after successful 5 
eradication of H. pylori. 6 
 Previous studies have shown that the risk of gastric cancer was increased by 7 
43% among PPI users but the major confounding factor, H. pylori, was not 8 
adjusted in these analyses and the causal relationship may be biased.  9 
 10 
What are the new findings? 11 
 Long-term PPI use was associated with a 2.4-fold increase in gastric cancer risk 12 
in H. pylori-infected subjects who had received eradication therapy. 13 
 The risk of gastric cancer increases with the dose and duration of PPI use.  14 
 15 
How might it impact on clinical practice in the foreseeable future? 16 
 Physicians should exercise cautions when prescribing long-term PPI to H. 17 
pylori-infected individuals even after successful eradication of H. pylori. 18 
 19 
 7 
INTRODUCTION 1 
Gastric cancer is the third leading cause of cancer related mortality in the world.1  2 
Although Helicobacter pylori (H. pylori) eradication has been shown to reduce the 3 
risk of gastric cancer development by 33-47%2, 3, a considerable proportion of these 4 
individuals continues to progress to gastric cancer even after eradication of H. pylori. 5 
Apart from baseline gastric histology at the time of eradication4, data are sparse on 6 
other modifiable risks of gastric cancer development, particularly on the role of 7 
concurrent medications.  8 
 9 
Proton pump inhibitors (PPIs) are among the most commonly prescribed medications 10 
in the world since the first PPI has become available in the 1980s.5 Although PPIs are 11 
generally considered safe, recent data have demonstrated various adverse effects 12 
associated with long-term use of PPIs including bone fracture,6 Clostridium difficile 13 
infection,7 pneumonia,8 myocardial infarction and even stroke.9 Apart from the 14 
systemic adverse effects, there are also concerns on the long-term safety profile of 15 
PPIs in the stomach. The use of PPIs is associated with profound acid suppression, 16 
which could worsen atrophic gastritis.10 The risk is considerably higher in individuals 17 
infected with H. pylori who are susceptible to the development of corpus atrophy.11 18 
Moreover, PPIs stimulate the production of gastrin, which is a potent growth factor, 19 
 8 
and hypergastrinemia has been shown to induce hyperplasia of enterochromaffin-like 1 
cells.11 A recent meta-analysis showed that the risk of gastric cancer is increased by 2 
43% among PPI users.12 However, these studies included both H. pylori-infected and 3 
H. pylori-negative subjects. Although previous short-term studies had suggested the 4 
resolution of corpus atrophy with H. pylori eradication therapy in patients with 5 
gastroesophageal reflux disease13, 14, it remains uncertain whether the potential risk of 6 
PPIs on gastric cancer development could be eliminated by clearance of H. pylori.  7 
 8 
This population-based study aimed to determine the risk of gastric cancer 9 
development among individuals who had received treatment for H. pylori with focus 10 
on the role of long-term PPIs.  11 
 12 
 13 
  14 
 9 
METHODS 1 
Data source  2 
Data were retrieved from Clinical Data Analysis and Reporting System (CDARS) of 3 
the Hong Kong Hospital Authority. The Hospital Authority is the sole public 4 
healthcare provider for primary, secondary and tertiary health services through 7 5 
hospital clusters and covers 87-94 % of all secondary and tertiary care in Hong Kong 6 
with a population of around 7.3 million.15 Under this system, there are altogether 42 7 
public hospitals, 47 specialist out-patient clinics and 73 general out-patient clinics. All 8 
essential clinical information including patients’ demographics, hospitalization, visits 9 
to outpatient clinics and emergency departments, diagnoses, laboratory results, 10 
procedures, prescriptions, dispensing of medications and death are recorded in 11 
CDARS, which is an electronic database managed by the HA. This database was 12 
established in 1995 for both audit and research purposes. To protect patient’s 13 
confidentiality, each patient is assigned a unique, anonymous patient identifier, which 14 
is linked to all the clinical data contained in CDARS. A number of high-quality, 15 
population-based studies16-18 and multinational pharmacovigilance studies19, 20 have 16 
been conducted based on the data retrieved from CDARS. The International 17 
Classification of Diseases, Ninth Revision (ICD-9) was used for disease coding and 18 
previous studies have verified the accuracy of the coding in CDARS with high 19 
 10 
positive and negative predictive values of more than 90%.17, 21 The study protocol was 1 
approved by the Institutional Review Board of the University of Hong Kong and the 2 
West Cluster of Hospital Authority, Hong Kong (reference no: UW 16-545).    3 
 4 
Study Subjects  5 
We identified all adult patients who were aged 18 years or above and had been 6 
prescribed a minimum of 7-day course of clarithromycin-based triple therapy for H. 7 
pylori infection in outpatient clinics between 1 January 2003 and 31 December 2012. 8 
H. pylori infection was diagnosed by either upper endoscopy with biopsy based tests 9 
or urea breath test in this study, as serology and stool antigen tests were not available 10 
in the public hospitals in Hong Kong. The prescription of clarithromycin-based triple 11 
therapy was identified by the co-prescription of one of the proton pump inhibitors 12 
(PPIs) with clarithromycin and either amoxicillin or metronidazole, with doses as 13 
described previously.22 The start date of the prescriptions should be the same, with an 14 
overlapping duration of seven to 14 days. Clarithromycin-based triple therapy was the 15 
first-line therapy for H. pylori in Hong Kong during the study period due to the low 16 
clarithromycin resistance rate (8%)23 and overall high eradication rate (> 90%).24 To 17 
remove the confounding effects of symptoms from gastric cancer leading to the use of 18 
PPIs or histamine 2-receptor antagonist (H2RA) (i.e. protopathic bias), prescriptions 19 
 11 
of these agents started within six months prior to the gastric cancer diagnosis were 1 
excluded from analyses.25, 26  2 
  3 
Since gastric cancer can masquerade as non-healing ulcer, all patients with gastric 4 
ulcer diagnosed at the time of or any time after receiving triple therapy were excluded. 5 
As there may be a delay in the diagnosis of gastric cancer, patients who developed 6 
gastric cancer within the first year of H. pylori eradication therapy were excluded. 7 
Patients with history of gastric cancer, previous gastrectomy or those who failed triple 8 
therapy were also excluded to ensure homogeneity of our study cohort. We defined 9 
failure of H. pylori eradication therapy as the requirement of subsequent prescriptions 10 
of (a) repeated course of clarithromycin-based triple therapy; (b) a second-line 11 
therapy (bismuth-based quadruple therapy or PPI-levofloxacin-amoxycillin); or (c) a 12 
third-line therapy (rifabutin-based therapy). Figure 1 illustrates the inclusion and 13 
exclusion process of patients in this study. The time frame of the study is shown in 14 
eFigure 1.  15 
 16 
Outcomes 17 
The primary outcome was the development of gastric adenocarcinoma. The 18 
observation period commenced from the date of first triple therapy prescription (i.e. 19 
 12 
index date) and was censored at the date of diagnosis of gastric cancer, death, or end 1 
of the study (31 December 2015). The date of diagnosis of gastric cancer was defined 2 
as the first date of hospitalization for gastric cancer workup or treatment. Follow-up 3 
duration of individual patient was defined as the duration of observation between the 4 
index date and the censored date. All cases of gastric adenocarcinoma were identified 5 
in accordance with the ICD-9 (International Classification of Diseases, ninth revisions) 6 
(eTable 1). We excluded patients with diagnosis of gastric lymphoma in this study. In 7 
order to ensure the validity of the case definition, a list of diagnostic codes was 8 
reviewed and finalized by a group of gastroenterologists.  9 
 10 
Study variables 11 
The primary exposure of interest was the subsequent prescription of PPIs after 12 
receiving the triple therapy for H. pylori. Potential confounders for gastric cancer 13 
development were also evaluated including the age of receiving triple therapy, sex, 14 
smoking status, alcohol consumption, past history of gastric ulcer, past history of 15 
duodenal ulcer, other comorbidities (including diabetes mellitus, hypertension, 16 
dyslipidemia, obesity, ischemic heart disease, atrial fibrillation, congestive heart 17 
failure, stroke, chronic renal failure and cirrhosis) and uses of various medications 18 
 13 
including statin, metformin, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), 1 
cyclooxygenase-2 (COX-2) inhibitors, clopidogrel and H2RA.  2 
 3 
PPIs are much more potent than H2RA in terms of gastric acid suppression,27 and 4 
previous studies did not reveal any association between gastric cancer development 5 
and H2RA.25, 28, 29 Hence, H2RA was selected as a negative control exposure in our 6 
study. If there is a positive association between H2RA and gastric cancer, this will 7 
suggest some unmeasured factors that confound the causal relationship between PPIs 8 
and gastric cancer development including protopathic bias.  9 
 10 
To further control for possible confounding effects, another cohort of PPIs users (at 11 
least weekly use) who had not received H. pylori eradication therapy and fulfilled the 12 
same inclusion and exclusion criteria as our H. pylori eradication cohort was recruited 13 
for comparison. These PPI users who had not received H. pylori eradication therapy 14 
were then matched with the PPI users who had received H. pylori eradication therapy 15 
(n = 3,271) by age (+/- 5 years), sex, duration of follow-up (+/- 2 years) and 16 
frequency of PPI use (+/- 0.3) in a 1:4 ratio. The incidence rates of gastric cancer in 17 
the two PPI cohorts were then compared. 18 
 14 
We used similar approaches as adopted by Poulsen et al28 to ascertain smoking status 1 
and alcohol consumption as these data was not available in the CDRAS. Smoking was 2 
identified by the ICD-9 code of V15.82 while chronic obstructive pulmonary disease 3 
(COPD) (ICD-9 codes: 491, 492, 496) was also used as proxy of heavy smoking. 4 
Heavy alcohol consumption was identified by alcohol-related diseases, including 5 
hepatic and gastrointestinal diseases, neurological and psychiatric diseases (ICD-9: 6 
291, 303, 305.0, 571, 980). The diagnostic codes of other variables are listed in 7 
eTable 1.  8 
 9 
In the primary analysis, the exposure categories of various medications were 10 
categorized similarly into non-regular use (<weekly use; reference group) and regular 11 
use (at least weekly use) as described by Thrift et al.30 The treatment duration of each 12 
prescription of a particular medication was defined as the difference between the 13 
prescription start date and end date within the observation period. The total treatment 14 
duration of that particular medication was then calculated by summing up the 15 
treatment duration of each prescription.  16 
 17 
To study the dose-response relationship of PPIs on gastric cancer, the frequency of 18 
PPIs use was classified into three groups: (i) <weekly use, (ii) weekly to <daily use 19 
 15 
and (iii) daily use. The frequency of PPIs use was calculated by dividing the total 1 
treatment duration by the duration of follow-up.  The effect of PPIs was also studied 2 
with regard to the duration of therapy into ≥ 1 year, ≥ 2 years and ≥ 3 years as defined 3 
in a recent meta-analysis.12 4 
 5 
Data validation  6 
As individual’s identification is anonymized in the electronic database (CDARS), we 7 
could only retrieve detailed information of individual gastric cancer cases who were 8 
managed in our centre (Queen Mary Hospital), which is a tertiary referral centre and a 9 
university teaching hospital. Of the 153 gastric cancer cases, 12 cases were managed 10 
in our centre and were reviewed in details for gastric histology. 11 
 12 
Statistical analyses  13 
All statistical analyses were performed using R version 3.2.3 (R Foundation for 14 
Statistical Computing) statistical software. Continuous variables were expressed as 15 
median and interquartile range (IQR). Mann-Whitney U-test was used to compare 16 
continuous variables of two groups. Chi-square test or Fisher’s exact test was applied 17 
for categorical variables. Cox proportional hazards model was used to estimate the 18 
crude and adjusted hazard ratio (HR) of gastric cancer development with PPIs use. To 19 
 16 
control for the confounders, propensity score adjustment was performed. Propensity 1 
scores were derived from logistic regression to represent the conditional probability of 2 
PPIs use given the other variables (age, sex, comorbidities and concomitant 3 
medications). To further reduce the bias from unmeasured confounding, individuals 4 
with extreme scores in the upper and lower tails of the propensity score distribution 5 
were excluded.31 In order to establish the cut-points for trimming, we constructed 20 6 
categories of 5% each for the distribution of scores.  7 
  8 
In the primary analysis, the first and 20th propensity score strata were trimmed, and 9 
the estimated propensity score was then used as an adjustment variable in the Cox 10 
proportional hazards model to derive the HR (propensity score adjustment with 11 
trimming). A sensitivity analysis was also performed without trimming the extreme 12 
propensity score strata (propensity score adjustment without trimming). In addition,  13 
the HR by univariate and multivariable analyses (with all covariates included) from 14 
Cox proportional hazards model were presented. For subgroup analysis, the risk of 15 
gastric cancer with PPIs use was stratified according to the tumour sites (cardia and 16 
non-cardia regions). Moreover, we estimated the propensity score adjusted absolute 17 
difference in gastric cancer risk for PPIs vs non-PPIs use by the adjusted HR minus 1, 18 
followed by the multiplication of the crude incidence rates among patients who did 19 
 17 
not use PPIs.32 As H2RA was selected as a negative control exposure, propensity 1 
scores were also derived from logistic regression to represent the conditional 2 
probability of H2RA use given the other variables. The HR of gastric cancer with 3 
H2RA was determined by propensity score adjustment after trimming. All statistical 4 
tests were two-sided, and a p-value of <0.05 was used to define statistical significance.  5 
  6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 18 
RESULTS 1 
Patient Characteristics  2 
A total of 74,612 subjects had received clarithromycin-based triple therapy during the 3 
10-year period. After excluding patients who did not fulfil our inclusion criteria 4 
(Figure 1), 63,397 subjects were included in the final analysis. The median age of this 5 
cohort at the time of H. pylori eradication therapy was 54.7 years (IQR: 46.0 – 65.4 6 
years) and 46.5% were men. The median follow-up was 7.6 years (IQR: 5.1 – 10.3 7 
yeas) and the total follow-up duration was 483,259 person-years. The baseline 8 
characteristics of the whole cohort and the subgroups according to PPIs and H2RA 9 
use are shown in Tables 1 and 2 .  10 
 11 
Risk of Gastric Cancer Development 12 
One hundred and fifty-three (0.24%) subjects developed gastric cancer after H. pylori 13 
eradication therapy. Among them, 31 (20.3 %) cancer were in the cardia and 95 (62.1 14 
%) in the non-cardia regions. The sites were not specified in the remaining 27 (17.6%) 15 
cases (ICD-9: 151.9). Similar ratio were observed for all the stomach cancer cases 16 
(n=12,898) diagnosed in Hong Kong during the study period (13.4% in cardia, 67.5% 17 
in non-cardia and 19.1% cases with sites unspecified). 18 
 19 
 19 
Twelve out of 153 patients (7.8%) with gastric cancer who fulfilled the inclusion and 1 
exclusion criteria from our centre were verified for histological findings. All patients 2 
were negative for H. pylori on gastric biopsies at the time of diagnosis and had 3 
underlying chronic gastritis, while intestinal metaplasia was reported in 5 cases.  4 
 5 
The median age at cancer diagnosis was 71.4 years (IQR 61.1 – 81.5 years). Patients 6 
who developed gastric cancer received H. pylori eradication therapy at a median age 7 
of 65.4 years (IQR 56.4 – 76.2 years), and the median time from H. pylori treatment 8 
to cancer development was 4.9 years (IQR: 2.7 – 7.2 years). The overall incidence 9 
rate of gastric cancer in this cohort was 3.2 per 10,000 person-years. The incidence 10 
rate of gastric cancer for each year is shown in eTable 2, which ranged from 2.5 to 11 
5.8 per 10,000 person-years. Notably, there were no gastric cancer cases within the 12 
first year of follow-up, as these cases were excluded.  13 
 14 
Association of PPIs use and risk of gastric cancer  15 
Table 3 and eTable 3 show the associations between PPIs use and gastric cancer 16 
development after H. pylori therapy. PPIs users (at least weekly use) were found to 17 
have a higher risk of gastric cancer (HR 2.44, 95% CI 1.42 – 4.20) after propensity 18 
score adjustment with trimming. Sensitivity analysis confirms the association of PPIs 19 
 20 
use with gastric cancer development by either multivariable analysis (HR 2.19, 95% 1 
CI 1.31 – 3.66) or propensity score adjustment without trimming (HR 2.14, 95% CI 2 
1.27 – 3.58). 3 
The propensity score adjusted absolute risk difference for PPIs use compared with 4 
non-PPIs use was 4.29 excess gastric cancer (95% CI 1.25 to 9.54) per 10,000 person-5 
years. 6 
 7 
After stratification by the site of tumour, PPIs use was only found to be significantly 8 
associated with an increased risk of non-cardia gastric cancer (HR 2.59, 95% CI 1.42 9 
– 4.72) but not cardia cancer (HR 1.97, 95% CI 0.57 – 6.82). Sensitivity analysis 10 
yielded similar results. 11 
 12 
Frequency and duration of PPIs use on risk of gastric cancer   13 
A total of 3,271 (5.2%) patients in this cohort had used PPIs and the median duration 14 
of PPI use was 2.7 years (IQR: 1.5 – 5.1 years). Among them, 19 (0.6%) developed 15 
gastric cancer (8.1 per 10,000 person-years). We further determined the frequency and 16 
duration of PPIs use on gastric cancer development. Patients were first stratified 17 
according to the frequency of PPI use (Table 4) into three groups as described in the 18 
Method section. When compared with the reference group (< weekly use), there was a 19 
 21 
progressive increase in the risk of gastric cancer with more frequent use of PPIs (HR  1 
2.43 [95% CI 1.37 – 4.31] for “weekly to < daily use”, and HR 4.55 [95% CI 1.12 – 2 
18.52] for “daily use”). Sensitivity analysis yielded similar results (eTables 2 and 3). 3 
Furthermore, the effect of long-term PPIs on gastric cancer development was studied 4 
with regard to the duration of PPIs therapy (≥ 1 year, ≥ 2 years and ≥ 3 years). As 5 
shown in Table 4, the risk increased with longer duration of PPIs use (HR 5.04 [95% 6 
CI 1.23 – 20.61] for at least 1 year of use; HR 6.65 [95% CI 1.62 – 27.26] for at least 7 
2 years of use and HR 8.34 [95% CI 2.02 – 34.41] for at least 3 years of use).  8 
 9 
Association of H2RA use and risk of gastric cancer  10 
To test for potential confounding, H2RA was used as a negative control exposure. 11 
The HR of gastric cancer with H2RA use on univariate analysis was 0.95 (95% CI 12 
0.67 – 1.33), while the HR from propensity score adjustment with trimming was 0.72 13 
(95% CI 0.48 – 1.07). 14 
 15 
Comparison of the incidence rates of gastric cancer with a matched cohort of 16 
PPIs users who had not received H. pylori eradication therapy 17 
To further check for potential confounding, another cohort of PPI users (at least 18 
weekly use) who had not received H. pylori eradication therapy were included for 19 
 22 
comparison. Altogether, 142,460 PPI users without H. pylori eradication therapy were 1 
identified with a total of 705,094 person-years follow-up. Among them, there were 59 2 
gastric cancer cases making a crude incidence rate of 0.8 cases per 10,000 person-3 
years. After matching, the incidence rate was 8.1 case per 10,000 person-years and 1.0 4 
cases per 10,000 person-years in the two cohorts of  PPIs users with and without  H. 5 
pylori eradication therapy, respectively (incidence rate ratio 0.12; 95% CI 0.05 – 0.26) 6 
(Table 5).  7 
  8 
 23 
DISCUSSION 1 
In this population-based study that addressed the risk of gastric cancer development in 2 
H. pylori-infected individuals after receiving eradication treatment, we found that 3 
long-term use of PPIs increased the risk of gastric cancer development. Our results 4 
showed that even after apparent successful H. pylori eradication therapy, those who 5 
used long term PPIs had a 2.4-fold increase in risk of gastric cancer development than 6 
non-users. This increase in risk was not observed among H2RA users. Further 7 
analysis demonstrated a dose- and time-dependent increase in the HRs of gastric 8 
cancer with PPIs use, with the highest risk observed in daily users of PPIs (HR 4.55). 9 
Patients who took PPIs daily for at least three years were at the highest risk (HR 8.34). 10 
Notably, the increase in HR was limited to non-cardia cancer, although this result 11 
should be interpreted with caution as this subgroup analysis has a relatively small 12 
number of cardia cancers.  13 
 14 
Gastric atrophy is generally considered to be a precursor of gastric cancer, which is 15 
usually associated with chronic H. pylori infection. While PPIs are potent acid 16 
suppressors, there have been concerns on the possible worsening of gastric atrophy by 17 
long term PPIs and the associated increase in gastric cancer risk.10, 12 Most published 18 
data supported that long term PPIs could worsen corpus gastritis and atrophy, 19 
particularly in H. pylori-positive subjects.10, 33 Although the long-term use of PPIs for 20 
 24 
more than 12 months was shown to be associated with an increased risk of gastric 1 
cancer,12 these results are largely confounded by the unknown prevalence of H. pylori 2 
in the study population.25, 28, 29 On the other hand, treatment of H. pylori in patients 3 
with reflux esophagitis requiring long-term PPIs was found to eliminate gastric 4 
mucosal inflammation and possibly induce regression of corpus glandular atrophy.13 5 
Hence, current guideline recommends eradication of H. pylori prior to the initiation of 6 
long-term PPIs.34 Whilst gastroesophageal reflux is related to over-production of 7 
gastric acid and hence a lower prevalence of corpus atrophy, these patients may not be 8 
the ideal population to study relationship between PPI use and worsening of corpus 9 
atrophy and gastric cancer. There is so far no long-term data to support that H. pylori 10 
eradication is sufficient in preventing cancer development in these individuals who 11 
use long-term PPIs.  12 
 13 
To our knowledge, this is the first study to demonstrate that long-term PPIs use, even 14 
after H. pylori eradication therapy, is still associated with an increased risk of gastric 15 
cancer. This is likely related to the profound acid suppression of PPIs that worsens 16 
atrophic gastritis, particularly in those patients with established gastric atrophy as a 17 
result of chronic H. pylori-induced inflammation. The lack of association between 18 
H2RA uses and gastric cancer development further supports the specific role of PPIs 19 
 25 
on gastric cancer development. One of the strengths of our study is the use of data 1 
from population-based database with complete information on subsequent diagnoses 2 
and drug prescriptions, thus minimizing the selection, information and recall biases. 3 
As all medications are dispensed by the hospital pharmacy at a very low cost to 4 
patients (i.e. £1 per item for 16 weeks), the prescription records are expected to be 5 
identical to dispensing records. The large sample size and the relatively long duration 6 
of follow-up (median 7.6 years) allow for more precise effect estimation of gastric 7 
cancer risk attributed to various factors, and enable subgroup analysis. The 8 
association was also consistent in both the frequency and duration of PPIs treatment 9 
which demonstrated a dose- and time-response trend suggestive of a cause-effect 10 
relationship.  11 
 12 
Another strength of this study was the use of a strict exclusion criteria as well as 13 
propensity score adjustment to control for potential confounders in determining the 14 
causal relationship between PPIs use and gastric cancer development. The results 15 
remained significant by various sensitivity analyses. In addition, we recruited patients 16 
with successful H. pylori eradication only. In fact, failure to adjust for H. pylori 17 
infection is one of the major concerns in studying the effect of PPIs on gastric cancer 18 
risk in previous studies.25, 28, 29 The indication bias  and protopathic bias was another 19 
 26 
major concern that leads to the undetermined conclusion of the causal relationship 1 
between PPIs use and gastric cancer development in previous studies.25, 28, 29 First, as 2 
gastric cancer can present with dyspepsia leading to an increase use of PPIs, all 3 
prescriptions of PPIs in the six months preceding the diagnosis of gastric cancer were 4 
excluded to avoid protopathic bias in this study. We used six months as the priori cut-5 
off because previous study that specifically addressed the issue of protopathic bias 6 
showed that this was the most appropriate lag-time to be applied for the assessment of 7 
PPIs exposure on gastric cancer risk in pharmaco-epidemiological studies.26 Moreover, 8 
PPIs are not approved as first-line therapy for dyspepsia in the Hong Kong Hospital 9 
Authority, and H2RAs are usually the recommended treatment for this indication. 10 
One would anticipate a similar increase in gastric cancer risk among those taking 11 
H2RAs (negative control exposure) if there was significant indication bias in this 12 
cohort. The minimization of protopathic bias and indication bias was further 13 
supported by the findings that the matched cohort of PPIs users without H. pylori 14 
eradication therapy had the lowest incidence rate when compared to the two post-H. 15 
pylori eradicated cohorts (Table 5). By comparing the incidence rate of gastric cancer 16 
of a matched cohort of PPIs users who had not received H. pylori eradication therapy, 17 
we showed that H. pylori infection, even prior infection, was a more important factor 18 
than PPIs use in determining gastric cancer risk. PPIs increase the risk of gastric 19 
 27 
cancer development likely only in the context of underlying H. pylori-associated 1 
chronic gastritis and atrophy only. Second, we excluded patients who had active 2 
gastric ulcer diagnosed at the time of H. pylori eradication therapy or during 3 
surveillance intervals as gastric cancer may masquerade as non-healing gastric ulcer.  4 
 5 
Our study has several limitations. First, the information of some risk factors (e.g. diet, 6 
family history and socioeconomic status) could not be obtained from the electronic 7 
database. Second, the identification of certain parameters (smoking, alcohol use and 8 
obesity) via coding may underestimate their true prevalence, as only patients who had 9 
heavy consumption of smoking and alcohol or who were morbidly obese would be 10 
coded. Third, although patients who failed triple therapy were identified by the 11 
repeated prescription of clarithromycin-based triple therapy or prescription of second 12 
and third line therapies, it remained possible that a small proportion of patients who 13 
failed H. pylori eradication therapy might be missed. In this study, about 13.2% of 14 
patients had received a second course of eradication therapy which was compatible 15 
with the observed success rate of clarithromycin-based triple therapy in our 16 
population with relatively low prevalence of clarithromycin resistance during the 17 
study period.23 In addition, we have validated the negative H. pylori status of all 12 18 
gastric cancer cases from our hospital. Fourth, although we included more than 19 
 28 
63,000 H. pylori-infected subjects, the small number of gastric cancer cases did not 1 
allow for any meaningful evaluation of the dosage effect and role of different PPIs. 2 
However, it was recently shown that there was no difference in the gastric cancer risk 3 
between longer and shorter-acting PPIs.35 Fourth, PPIs users may have a higher 4 
chance to undergo endoscopy than non-PPI users, and therefore surveillance bias may 5 
lead to a higher risk of gastric cancer as observed in current study. However, as 6 
shown in eTable  7 
 8 
Lastly, the detailed histological findings of gastric biopsies at baseline and at the time 9 
of gastric cancer development were not available in the CDARS, precluding more in-10 
depth analysis between the association of PPIs and baseline histology on gastric 11 
cancer development. 12 
 13 
CONCLUSION 14 
Long-term use of PPIs in subjects with prior H. pylori eradication was still associated 15 
with an increased risk of gastric cancer development, particularly for non-cardia 16 
cancer. There was also a clear dose- and time-response trend of PPI uses and gastric 17 
cancer risk. Physicians should therefore exercise cautions when prescribing long-term 18 
PPIs to these patients even after successful eradication of H. pylori.  19 
 29 
 1 
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FIGURE LEGEND 1 
 2 
Figure 1: Study patient selection flow diagram 3 
Abbreviations: GC, gastric cancer; GU, gastric ulcer 4 
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 6 
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Table 1. Characteristics of PPI and non-PPI users  1 
 2 
 All 
(n=63,397) 
PPI users 
(n=3,271) 
Non-PPI users 
(n=60,126) 
Age at triple therapy 
(years)*  
54.7 (46.0 – 65.4) 64.1 (53.6 – 75.3) 54.3 (45.7 – 64.7) 
Male sex (n, %)  29499 (46.5%) 1641 (50.2%) 27858 (46.3%) 
Duration of follow-
up (years)*  
7.6 (5.1 – 10.3) 7.4 (4.5 – 10.0) 7.6 (5.2 – 10.3) 
Smoking (n, %)  1629 (2.6%) 162 (5.0%) 1467 (2.4%) 
Alcohol (n, %)  
Dyspepsia (n, %) 
GERD (n, %) 
552 (0.9%) 
4145 (6.5%) 
3278 (5.2%) 
50 (1.5%) 
262 (8.0%) 
593 (18.1%) 
502 (0.8%) 
3883 (6.5%) 
2685 (4.5%) 
History of GU (n, %)  1268 (2.0%) 153 (4.7%) 1115 (1.9%) 
History of DU (n, %)  1897 (3.0%) 139 (4.2%) 1758 (2.9%) 
DM (n, %)  7383 (11.6%) 772 (23.6%) 6611 (11.0%) 
Hypertension (n, %)  13065 (20.6%) 1334 (40.8%) 11731 (19.5%) 
Dyslipidemia (n, %) 5045 (8.0%) 579 (17.7%) 4466 (7.4%) 
Obesity 637 (1.0%) 61 (1.9%) 576 (1.0%) 
IHD (n, %)  5701 (9.0%) 906 (27.7%) 4795 (8.0%) 
AF (n, %)  2404 (3.8%) 371 (11.3%) 2033 (3.4%) 
CHF (n, %)  2512 (4.0%) 463 (14.2%) 2049 (3.4%) 
Stroke (n, %)  3965 (6.3%) 561 (17.2%) 3404 (5.7%) 
CRF (n, %)  1388 (2.2%) 236 (7.2%) 1152 (1.9%) 
Cirrhosis (n, %)  1037 (1.6%) 98 (3.0%) 939 (1.6%) 
Statins (n, %)   13180 (20.8%) 1351 (41.3%) 11829 (19.7%) 
Metformin (n, %)   7935 (12.5%) 605 (18.5%) 7330 (12.2%) 
Aspirin (n, %)   8965 (14.1%) 1358 (41.5%) 7607 (12.7%) 
NSAIDs/ 
COX-2 inhibitors  
(n, %)   
3556 (5.6%) 391 (12.0%) 3165 (5.3%) 
Clopidogrel (n, %)   980 (1.5%) 200 (6.1%) 780 (1.3%) 
H2RA (n, %)   21729 (34.3%) 1499 (45.8%) 20230 (33.6%) 
* Age was expressed as median (years) with interquartile range 
Categorical variables were expressed as number (%) 
Drug use was defined as at least weekly use, and expressed as number (%) 
PPIs, proton pump inhibitors; GERD, gastroesophageal reflux disease; GU, gastric ulcer; DU, duodenal 
ulcer; DM, diabetes mellitus; IHD, ischemic heart disease; AF, atrial fibrillation; CHF, congestive heart 
failure; CRF, chronic renal failure; NSAIDs, non-steroidal anti-inflammatory drugs; COX-2, 
cyclooxygenase-2; H2RA, histamine 2 receptor antagonist 
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Table 2. Characteristics of H2RA and non-H2RA users  1 
 2 
 All 
(n=63,397) 
H2RA users 
(n=21,729) 
Non- H2RA users 
(n=41,668) 
Age at triple therapy 
(years)*  
54.7 (46.0 – 65.4) 60.0 (51.6 – 71.0) 52.0 (43.4 – 61.6) 
Male sex (n, %)  29499 (46.5%) 9454 (43.5%) 20045 (48.1%) 
Duration of follow-
up (years)*  
7.6 (5.1 – 10.3) 7.2 (4.8 – 9.8) 7.8 (5.3 – 10.5) 
Smoking (n, %)  1629 (2.6%) 863 (4.0%) 766 (1.8%) 
Alcohol (n, %)  
Dyspepsia (n, %) 
GERD (n, %) 
552 (0.9%) 
4145 (6.5%) 
3278 (5.2%) 
232 (1.1%) 
1826 (8.4%) 
1629 (7.5%) 
320 (0.8%) 
2319 (5.6%) 
1649 (4.0%) 
History of GU (n, %)  1268 (2.0%) 446 (2.1%) 822 (2.0%) 
History of DU (n, %)  1897 (3.0%) 503 (2.3%) 1394 (3.3%) 
DM (n, %)  7383 (11.6%) 3885 (17.9%) 3498 (8.4%) 
Hypertension (n, %)  13065 (20.6%) 7137 (32.8%) 5928 (14.2%) 
Dyslipidemia (n, %) 5045 (8.0%) 2939 (13.5%) 2106 (5.1%) 
Obesity 637 (1.0%) 351 (1.6%) 286 (0.7%) 
IHD (n, %)  5701 (9.0%) 3560 (16.4%) 2141 (5.1%) 
AF (n, %)  2404 (3.8%) 1468 (6.8%) 936 (2.2%) 
CHF (n, %)  2512 (4.0%) 1512 (7.0%) 1000 (2.4%) 
Stroke (n, %)  3965 (6.3%) 2466 (11.3%) 1499 (3.6%) 
CRF (n, %)  1388 (2.2%) 814 (3.7%) 574 (1.4%) 
Cirrhosis (n, %)  1037 (1.6%) 425 (2.0%) 612 (1.5%) 
Statins (n, %)   13180 (20.8%) 7401 (34.1%) 5779 (13.9%) 
Metformin (n, %)   7935 (12.5%) 3899 (17.9%) 4036 (9.7%) 
Aspirin (n, %)   8965 (14.1%) 6376 (29.3%) 2589 (6.2%) 
NSAIDs/ 
COX-2 inhibitors  
(n, %)   
3556 (5.6%) 3092 (14.2%) 464 (1.1%) 
Clopidogrel (n, %)   980 (1.5%) 602 (2.8%) 378 (0.9%) 
PPIs (n, %)   3271 (5.2%) 1499 (6.9%) 1772 (4.3%) 
* Age was expressed as median (years) with interquartile range 
Categorical variables were expressed as number (%) 
Drug use was defined as at least weekly use, and expressed as number (%) 
H2RA, histamine 2 receptor antagonist; GERD, gastroesophageal reflux disease; GU, gastric ulcer; DU, 
duodenal ulcer; DM, diabetes mellitus; IHD, ischemic heart disease; AF, atrial fibrillation; CHF, 
congestive heart failure; CRF, chronic renal failure; NSAIDs, non-steroidal anti-inflammatory drugs; 
COX-2, cyclooxygenase-2; PPIs, proton pump inhibitors;  
 3 
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Table 3. Association between PPI use and risk of gastric cancer for the whole cohort and 2 
according to gastric cancer sites (non-cardia and cardia regions) 3 
 4 
 
PPI 
frequency 
 
 
 
All GC  
 
Univariate  
analysis 
 
(n=63,397,  
GC=153) 
 
 
Multivariable  
analysis  
 
(n=63,397,  
GC=153) 
 
 
PS adjustment  
without trimming   
 
(n=63,397,  
GC=153) 
 
PS adjustment  
with trimming   
 
(n=57,057,  
GC=139) 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-
value 
 
Non-user 
(<weekly 
use) 
 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
At least 
weekly  
2.80 1.73 
– 
4.52 
0.003 2.19 1.31  
–  
  3.66 
0.003 2.14 1.27 
– 
3.58 
0.004 2.44 1.42 
– 
4.20 
0.002 
 5 
 
 
 
Non-
cardia GC 
 
(n=63,366,  
GC=122) 
 
 
(n=63,366,  
GC=122) 
 
 
(n=63,366,  
GC=122) 
 
(n=57,028,  
GC=112) 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-value 
 
Non-user 
(<weekly 
use) 
 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
At least 
weekly  
2.98 1.76 
– 
5.05 
0.001 2.56 1.46 
– 
4.49 
0.001 2.43 1.38 
– 
4.28 
0.002 2.59 1.42 
– 
4.72 
0.002 
 6 
 
 
 
Cardia 
GC 
 
(n=63,275,  
GC=31) 
 
 (n=63,275,  
GC=31) 
 
 
(n=63,275,  
GC=31) 
 
 
 (n=56,947,  
GC=27) 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-value 
 
Non-user 
(<weekly 
use)  
 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
At least 
weekly   
 
2.10 0.64 
– 
6.90 
0.222 1.24 0.35 
– 
4.34 
0.736 1.26 0.35 
– 
4.52 
0.722 1.97 0.57 
– 
6.82 
0.286 
Significant p-values were highlighted in bold  
HR, hazard ratio; 95% CI, 95% confidence interval; PPI, proton pump inhibitor; PS, propensity score; GC, gastric 
cancer 
 7 
 8 
 9 
 10 
 11 
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Table 4 . HRs and 95% CIs for the association between frequency and duration of PPI 1 
use and risk of gastric cancer (propensity score adjustment with trimming) 2 
 3 
 
 
 
 
PPI 
frequency 
Dose-response relationship 
 
(n=57,057, GC=139) 
 
HR 
 
 
95% CI p-value 
Non-user 
(<weekly 
use) 
 
Ref - - 
Weekly to 
<daily  
 
2.43 1.37 – 4.31 0.002 
Daily  4.55 1.12 – 18.52 0.034 
 
PPI 
frequency 
 
PPI use ≥ 1 year 
 
(n=50,932, GC=112) 
 
 
PPI use ≥ 2 years 
 
(n=49,462, GC=88) 
 
 
PPI use ≥ 3 years 
 
(n=48,511, GC=69) 
 
HR 95% CI p-
value 
HR 95% CI p-
value 
HR 95% CI p-
value 
 
Non-user 
(<weekly 
use) 
 
 
 Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
 
Ref 
 
- 
 
- 
Weekly to 
<daily  
 
1.81 0.90 – 3.64 0.098 0.98 0.31 – 3.17 0.979 0.58 0.08 – 4.23 0.590 
Daily  5.04 1.23 – 20.61 0.024 6.65 1.62 – 27.26 0.009 8.34 2.02 – 34.41 0.004 
          
Significant p-values were highlighted in bold  
HR, hazard ratio; 95% CI, 95% confidence interval; PPI, proton pump inhibitors; GC, gastric cancer 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
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Table 5. Comparison of incidence rates of gastric cancer in different cohorts according 1 
to PPI uses and prior H. pylori eradication therapy 2 
 3 
 
Before matching 
 
Number of 
patients 
 
Number of 
person-years 
 
Number of 
GC cases 
 
Incidence rate  
(per 10,000  
person-years) 
 
Incidence rate 
ratio with 
95% CI 
 
non-PPI users with 
prior HP therapy  
 
 
60,126 
 
459,864 
 
134 
 
2.9 
 
Ref 
 
PPI users with prior 
HP therapy  
 
 
3,271 
 
23,395 
 
19 
 
8.1 
 
2.81  
(1.68 – 4.43) 
PPI users without 
prior HP therapy  
 
142,460 705,094 59 0.8 0.29 
(0.21 – 0.39) 
 
After  
matching 
 
 
Number of 
patients 
 
Number of 
person-years 
 
Number of 
GC cases 
 
Incidence rate  
(per 10,000  
person-years) 
 
Incidence rate 
ratio with 95% 
CI 
 
PPI users with prior 
HP therapy  
 
 
3,270 
 
23,384 
 
19 
 
8.1 
 
Ref 
 
PPI users without 
prior HP therapy * 
 
 
13,080 
 
93,500 
 
9 
 
1.0 
 
0.12 
(0.05 – 0.26) 
     
* matched with age (+/- 5 years), sex, duration of follow-up (+/- 2 years) and frequency of PPI use (+/- 0.3) in a 
1:4 ratio 
PPI, proton pump inhibitor; HP, Helicobacter pylori; GC, gastric cancer; 95% CI, 95% confidence interval  
     
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
